

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Song et al.
Serial No.: 10/531,543
For: COMPOSITION FOR TREATING VIRUS INFECTION DISEASE
COMPRISING JAB1
Filed: April 15, 2005
Examiner: Not Yet Assigned
Art Unit: Not Yet Assigned
Confirmation No.: 4798
Customer No.: 27,623

Attorney Docket No.: 0002204USU/4105

Date: October 27, 2005

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with applicants' duty of disclosure under 37 C.F.R. §1.56, we are enclosing form PTO-1449 listing information that may be material to the patentability of this application.

37 C.F.R. 1.98 does not require a copy of U.S. patents or published U.S. patent applications to be included with an information disclosure statement. Accordingly, Applicant is not including a copy of any U.S. patent or published U.S. patent application.


Copies of available English abstracts of the aforementioned patents, patent applications and articles are enclosed herewith.

It should be understood that attention has been called to the citations that have been deemed to be pertinent to the claimed present invention. In concluding what was pertinent, the criteria employed was considered most appropriate in light of the invention shown in the present application. However, the Examiner or others may deem some other criteria to be just as appropriate or more appropriate. Therefore, the Examiner is respectfully urged to review the listed citations and to make the usual careful independent search for other prior art that may be pertinent.

Since this Information Disclosure Statement is being filed prior to the issuance of the first Office Action based on the merits, no petition or fee is required.

Applicants respectfully request favorable consideration and that this application be passed to allowance.

Respectfully submitted,



Charles N.J. Ruggiero

Reg. No. 28,468

Attorney for Applicant(s)

Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

One Landmark Square, 10th Floor

Stamford, CT 06901-2682

(203) 327-4500

CUSTOMER NO.: 27623

Sheet 1 of 1

FORM PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)

0002204USU/4105

Application Number

10/531,543

Applicant

Song et al.

Filing Date

April 15, 2005

Group Art Unit

Not Yet Assigned

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	Anninger et al., "Visual Loss with West Nile Virus Infection: A Wider Spectrum of a "New" Disease," Vol. 38, pp. e55-56, Dept. of Ophthalmology, Ohio State University Medical Center (2004).
	Agrawal et al., "Human Immunoglobulin as a Treatment for West Nile Virus Infection," Vol. 188, pp. 1-4, The Journal of Infections Diseases (2003).
	Watt et al., "Acute Undifferentiated Fever Caused by Infection with Japanese Encephalitis Virus," pp.704-706, Department of Retrovirology, Armed Forces Research Institute of Medical Sciences, (2003).
	Morrey et al., "Identification of active antiviral compounds against a New York isolate of West Nile virus," pp. 107-116, Antiviral Research 55 (2002).
	Caballero et al., "Interaction and Colocalization of PGP9.5 with JAB1 and p27Kip1," Vol. 21, pp.3003-3010, Oncogene (2002).
	Yang et al., "Induction of Inflammation by <i>West Nile Virus</i> Capsid through the Caspase-9 Apoptotic Pathway," Vol. 8, No. 12, pp. 1379-1384, Emerging Infectious Diseases, December 2002.
	"Efficacy of Interferon Alpha-2b and Ribavirin against <i>West Nile Virus</i> In Vitro," Vol. 8, No. 1, pp. 107-108, Emerging Infectious Diseases, January 2002.
	Bech-Otschir et al., "COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system," Vol. 20, No. 7, pp. 1630-1639, European Molecular Biology Organization (2001).
	Li et al., "p38 JAB1 Binds to the Intracellular Precursor of the Lutropin/Choriogonadotropin Receptor and Promotes Its Degradation," Vol. 275, No. 18, pp. 13386-13393, The Journal of Biological Chemistry (2000).
	Tomoda et al., "Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab 1," Vol. 398, pp. 160-165, Nature, 11 March 1999.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.